Tandem Diabetes Care (NASDAQ: TNDM) recently received a number of ratings updates from brokerages and research firms:
- 6/1/2026 – Tandem Diabetes Care was upgraded by Wells Fargo & Company from “buy” to “overweight”. They now have a $27.00 price target on the stock, up from $21.00.
- 5/28/2026 – Tandem Diabetes Care had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $17.00 price target on the stock, down from $22.00.
- 5/27/2026 – Tandem Diabetes Care was given a new $21.00 price target by The Goldman Sachs Group, Inc..
- 5/26/2026 – Tandem Diabetes Care was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 5/18/2026 – Tandem Diabetes Care had its price target lowered by Bank of America Corporation from $35.00 to $25.00. They now have a “neutral” rating on the stock.
- 5/11/2026 – Tandem Diabetes Care is now covered by Benchmark Co.. They set a “hold” rating on the stock.
- 5/11/2026 – Tandem Diabetes Care was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 5/11/2026 – Tandem Diabetes Care was given a new $55.00 price target by Barclays PLC. They now have an “overweight” rating on the stock.
- 5/11/2026 – Tandem Diabetes Care had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $31.00 price target on the stock, down from $35.00.
- 5/8/2026 – Tandem Diabetes Care was given a new $24.00 price target by Mizuho.
- 4/27/2026 – Tandem Diabetes Care was upgraded by Zacks Research from “hold” to “strong-buy”.
- 4/24/2026 – Tandem Diabetes Care was given a new $45.00 price target by Rothschild & Co Redburn.
- 4/20/2026 – Tandem Diabetes Care had its “buy” rating reaffirmed by TD Cowen. They now have a $28.00 price target on the stock, up from $25.00.
- 4/9/2026 – Tandem Diabetes Care had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $25.00. They now have a “neutral” rating on the stock.
Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.
The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.
Featured Stories
- Five stocks we like better than Tandem Diabetes Care
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.
